416 related articles for article (PubMed ID: 29617965)
21. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.
Kim HY; Hanrahan CF; Martinson N; Golub JE; Dowdy DW
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1435-1442. PubMed ID: 30606315
[TBL] [Abstract][Full Text] [Related]
22. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
Haas MK; Aiona K; Erlandson KM; Belknap RW
Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of a 12 country-intervention to scale up short course TB preventive therapy among people living with HIV.
Shin H; Jo Y; Chaisson RE; Turner K; Churchyard G; Dowdy DW
J Int AIDS Soc; 2020 Oct; 23(10):e25629. PubMed ID: 33107219
[TBL] [Abstract][Full Text] [Related]
24. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
Azadi M; Bishai DM; Dowdy DW; Moulton LH; Cavalcante S; Saraceni V; Pacheco AG; Cohn S; Chaisson RE; Durovni B; Golub JE
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1443-8. PubMed ID: 25517809
[TBL] [Abstract][Full Text] [Related]
26. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
[TBL] [Abstract][Full Text] [Related]
27. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.
Smith T; Samandari T; Abimbola T; Marston B; Sangrujee N
J Acquir Immune Defic Syndr; 2015 Nov; 70(3):e84-93. PubMed ID: 26258564
[TBL] [Abstract][Full Text] [Related]
28. Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.
Wheeler C; Mohle-Boetani J
Public Health Rep; 2019; 134(1_suppl):71S-79S. PubMed ID: 31059418
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Lai WA; Brethour K; D'Silva O; Chaisson RE; Zwerling AA
BMC Public Health; 2022 Dec; 22(1):2292. PubMed ID: 36476206
[TBL] [Abstract][Full Text] [Related]
30. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
[TBL] [Abstract][Full Text] [Related]
31. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
[TBL] [Abstract][Full Text] [Related]
32. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
33. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
[TBL] [Abstract][Full Text] [Related]
34. The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.
Sutton BS; Arias MS; Chheng P; Eang MT; Kimerling ME
Int J Tuberc Lung Dis; 2009 Jun; 13(6):713-8. PubMed ID: 19460246
[TBL] [Abstract][Full Text] [Related]
35. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
36. Isoniazid and Rifapentine Treatment Eradicates Persistent
Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
[No Abstract] [Full Text] [Related]
37. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis.
Pho MT; Swaminathan S; Kumarasamy N; Losina E; Ponnuraja C; Uhler LM; Scott CA; Mayer KH; Freedberg KA; Walensky RP
PLoS One; 2012; 7(4):e36001. PubMed ID: 22558301
[TBL] [Abstract][Full Text] [Related]
38. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S; Ramchandani R; Gupta A; Benson CA; Leon-Cruz J; Mwelase N; Jean Juste MA; Lama JR; Valencia J; Omoz-Oarhe A; Supparatpinyo K; Masheto G; Mohapi L; da Silva Escada RO; Mawlana S; Banda P; Severe P; Hakim J; Kanyama C; Langat D; Moran L; Andersen J; Fletcher CV; Nuermberger E; Chaisson RE;
N Engl J Med; 2019 Mar; 380(11):1001-1011. PubMed ID: 30865794
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE
Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955
[TBL] [Abstract][Full Text] [Related]
40. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M
Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
